Whereas adenosine itself exerted independent stimulatory and inhibitory effects on the adenylate cyclase activity of a platelet particulate fraction at low and high concentrations respectively, 2-substituted and N6-monosubstituted adenosines had stimulatory but greatly decreased inhibitory effects. Deoxyadenosines, on the other hand, had enhanced inhibitory but no stimulatory effects. The most potent inhibitors found were, in order of increasing activity, 9-(tetrahydro-2-furyl)adenine (SQ 22536), 2',5'-dideoxyadenosine and 2'-deoxyadenosine 3'-monophosphate. Kinetic studies on prostaglandin El-activated adenylate cyclase showed that the inhibition caused by either 2',5'-dideoxyadenosine or compound SQ 22536 was non-competitive with MgATP and that the former compound, at least, showed negative co-operativity; 50 % inhibition was observed with 4juM-2',5'-dideoxyadenosine or 13,uM-SQ 22536. These two compounds also inhibited both the basal and prostaglandin El-activated adenylate cyclase activities of intact platelets, when these were measured as the increases in cyclic [3H]AMP in platelets that had been labelled with [3H]adenine and were then incubated briefly with papaverine or papaverine and prostaglandin El. Both compounds, but particularly 2',5'-dideoxyadenosine, markedly decreased the inhibition by prostaglandin El of platelet aggregation induced by ADP or [arginine]vasopressin as well as the associated increases in platelet cyclic AMP, so providing further evidence that the effects of prostaglandin El on platelet aggregation are mediated by cyclic AMP. 2'-Deoxyadenosine 3'-monophosphate did not affect the inhibition of aggregation by prostaglandin E1, suggesting that the site of action of deoxyadenosine derivatives on adenylate cyclase is intracellular. Neither 2',5'-dideoxyadenosine nor compound SQ 22536 alone induced platelet aggregation. Moreover, neither compound potentiated platelet aggregation or the platelet release reaction when suboptimal concentrations of ADP, [arginine]vasopressin, collagen or arachidonate were added to heparinized or citrated platelet-rich plasma in the absence of prostaglandin El. These results show that cyclic AMP plays no significant role in the responses of platelets to aggregating agents in the absence of compounds that increase the platelet cyclic AMP concentration above the resting value.
Whereas adenosine itself exerted independent stimulatory and inhibitory effects on the adenylate cyclase activity of a platelet particulate fraction at low and high concentrations respectively, 2-substituted and N6-monosubstituted adenosines had stimulatory but greatly decreased inhibitory effects. Deoxyadenosines, on the other hand, had enhanced inhibitory but no stimulatory effects. The most potent inhibitors found were, in order of increasing activity, 9-(tetrahydro-2-furyl)adenine (SQ 22536), 2',5'-dideoxyadenosine and 2'-deoxyadenosine 3'-monophosphate. Kinetic studies on prostaglandin El-activated adenylate cyclase showed that the inhibition caused by either 2',5'-dideoxyadenosine or compound SQ 22536 was non-competitive with MgATP and that the former compound, at least, showed negative co-operativity; 50 % inhibition was observed with 4juM-2',5'-dideoxyadenosine or 13,uM-SQ 22536. These two compounds also inhibited both the basal and prostaglandin El-activated adenylate cyclase activities of intact platelets, when these were measured as the increases in cyclic [3H]AMP in platelets that had been labelled with [3H]adenine and were then incubated briefly with papaverine or papaverine and prostaglandin El. Both compounds, but particularly 2',5'-dideoxyadenosine, markedly decreased the inhibition by prostaglandin El of platelet aggregation induced by ADP or [arginine] vasopressin as well as the associated increases in platelet cyclic AMP, so providing further evidence that the effects of prostaglandin El on platelet aggregation are mediated by cyclic AMP. 2'-Deoxyadenosine 3'-monophosphate did not affect the inhibition of aggregation by prostaglandin E1, suggesting that the site of action of deoxyadenosine derivatives on adenylate cyclase is intracellular. Neither 2',5'-dideoxyadenosine nor compound SQ 22536 alone induced platelet aggregation. More Adenosine has been shown to have a biphasic effect on the unstimulated adenylate cyclase activity of platelet particulate fraction, activating the enzyme at low concentrations and inhibiting at higher concentrations (Haslam & Lynham, 1972) . In the presence of PGEj, a potent activator of adenylate cyclase, only the inhibitory activity of adenosine was observed. With intact platelets, the stimulatory activity of adenosine, mediated by externally orientated membrane receptors, predominated, but evidence for an attenuated inhibition of adenylate cyclase by adenosine acting at intracellular sites was * Abbreviations used: PGEj, prostaglandin El; IC5O, concentration giving 50%. inhibition.
Vol. 176 also obtained (Haslam & Rosson, 1975) . Inhibition by adenosine of adenylate cyclase from other tissues has frequently been observed (Moriwaki & Foa, 1970; Fain et al., 1972; McKenzie & Bar, 1973; Weinryb & Michel, 1974; Zenser, 1976) , and various deoxy analogues of adenosine have been found to be even more potent inhibitors, including 2',5'-dideoxyadenosine with adenylate cyclase from fat-cells (Fain et al., 1972) and epithelial cells (Zenser, 1976) and various 9-substituted adenines, including 9-(tetrahydro-2-furyl)adenine (SQ 22536), with adenylate cyclase from lung (Weinryb & Michel, 1974) . We therefore examined the effects of these and other adenosine analogues on platelet adenylate cyclase with a view to finding compounds with inhibitory but no stimulatory activity which could potentially be used in intact platelets to investigate the roles of cyclic AMP in platelet function. We were also encouraged to undertake this study by a preliminary report of Harris et al. (1975) indicating that some 9-substituted adenines, including compound SQ 22536, blocked the effects of PGE1 on platelets and by the finding of Zenser (1976) that 2',5'-dideoxyadenosine suppressed the increases in cyclic AMP in epithelial cells caused by cholera toxin.
Although it has been widely accepted that cyclic AMP mediates the inhibitory effects on platelet function of PGE1, adenosine and inhibitors of cyclic AMP phosphodiesterase (Salzman, 1972; Haslam, 1973 Haslam, , 1978 Mills & Macfarlane, 1976; Haslam et al., 1978) , the question whether or not decreases in platelet cyclic AMP occur during aggregation and may promote the aggregation process, as suggested by Salzman & Levine (1971) , has not been resolved. The fact that some aggregation can occur in the presence of increased platelet cyclic AMP concentrations rules out a role for decreases in platelet cyclic AMP as a necessary cause of aggregation (Haslam, 1973 (Haslam, , 1975 (Haslam, , 1978 , but does not eliminate the possibility that aggregation or release of platelet granule constituents could be facilitated by a decrease in the steady-state concentration of cyclic AMP in resting platelets. Measurements of changes in platelet cyclic AMP induced by aggregating agents have given widely divergent results and have not contributed to the solution of this problem (e.g. Salzman, 1972; Haslam, 1975) . In the last part of the present study, we have therefore attempted to determine whether or not cyclic AMP exerts a tonic inhibitory effect within the resting platelet by investigation of the effects on platelet function of adenosine analogues that inhibit adenylate cyclase. Some of our results have been reported in a preliminary form (Haslam, 1978; Haslam et al., 1977 Haslam et al., , 1978 (Haslam & Lynham, 1972) , except that they were finally resuspended in 150mM-Tris/HCI, pH 7.4. This suspension was rapidly frozen by using a solid Co2/acetone mixture and then shaken in a water bath at 37°C until just completely thawed, after which the lysate was centrifuged at 48000g for 20min at 0°C. The (Haslam & Rosson, 1975) of the method of Krishna et al. (1968) Measurement of changes in platelet cyclic AMP These were determined by extraction of labelled cyclic AMP from human heparinized platelet-rich plasma that had been preincubated for 90min with labelled adenine. The experimental procedures were as described previously (Haslam & Rosson, 1975) Haslam & Rosson (1975) and was expressed as a percentage of the total radioactivity incorporated into the platelets. As the standard errors of replicate measurements by this technique were on average only about 3% of the mean values (see e.g. Table 3 ), single assays were performed in large experiments, which were repeated with minor variations with platelet-rich plasma from at least three separate donors.
Studies on platelet aggregation and the release reaction These were carried out with either human citrated platelet-rich plasma [prepared from blood anticoagulated with 0.1 vol. of 3.8% (w/v) trisodium citrate] or human heparinized platelet-rich plasma, in both of which the platelet count was, if necessary, adjusted by dilution with platelet-free plasma to be within the range 350000-470000/mm3. Further details of the preparation of platelet-rich plasma have been given elsewhere (Haslam & Rosson, 1972 (Costa & Murphy, 1976) . The values obtained were corrected for any "4C found in supernatants from platelet-rich plasma to which only 0.154M-NaCl was added. Collagen and arachidonate were prepared for use as aggregating agents as described elsewhere Davies et al., 1976) .
Liquid-scintillation counting
Sample to be counted for radioactivity were freezedried to remove traces of 3H20, redissolved in 1 ml of water mixed with 7.5 ml of Quantafluor and counted for 3H and 14C in a Beckman LS 230 scintillation counter. Counting efficiencies were approx. 16 and 50 % for 3H and 'IC respectively, under dual-isotope counting conditions. Results were corrected for background radioactivity, channel cross-over and variations in quenching.
Results
Effects of adenosine analogues on the adenylate cyclase activity ofplatelet particulate fraction
We have previously reported that adenosine activates platelet adenylate cyclase at low concentrations (2-25,UM) and inhibits the enzyme at concentrations above about 100pM (Haslam & Lynham, 1972) . Two concentrations, 5 and 400pM, which clearly show these two effects of adenosine, were therefore chosen for comparison of a wide range of adenosine analogues (Table 1) . Modification of different parts of the adenosine molecule had radically different effects. Substitution in the 2-position decreased (2-benzylthioadenosine and 2-chloroadenosine) or abolished (2-hydrazinoadenosine and 2-azidoadenosine) the inhibitory activity observed with 400pM-adenosine, while some or all of the stimulatory activity observed with 5pUM-adenosine was retained. Of these four compounds, only 2-azidoadenosine was at least as effective an activator of adenylate cyclase as adenosine at 5pM and also showed marked stimulatory activity at 400,pM. All compounds tested with single substituents in the N6-position were stimulatory rather than inhibitory at 400pM, but showed less stimulatory activity at 5,pM than did adenosine. In contrast with the above compounds, analogues of adenosine in which the ribosyl moiety was modified by removal of one or more oxygen atoms had no stimulatory Table 1 . Effects of adenosine analogues on the adenylate cyclase activity ofplatelet particulate fraction
In this experiment the activity of platelet adenylate cyclase in the absence of adenosine or analogues was 0.59± 0.01nmol of cyclic AMP formed/lOmin per mg of protein (means+s.E.M. from five determinations on the same enzyme preparation). Assays in the presence of adenosine were carried out in quintuplicate and with other compounds in triplicate. The changes in mean adenylate cyclase activities ± the S.E. of the differences are expressed as percentages of the mean control value. The significance of changes (Student's t test) are indicated as follows: *2P < 0.05; **2P < 0.001.
Changes -11 ±4* -5±6 -46+2** -55±3** -20 ± 7* 400,pM -44±3** -10+2* -14+5* +29±2** +41 ± 5** +29±2** +50 ± 4** +44 ± 4** +37 ± 4** -71 ± 3** -79 ± 2** -72+2** -86+2** -92 + 2** -81 + 2** activity at either concentration tested and were, in several instances, potent inhibitors of adenylate cyclase at a concentration of 5AM as well as 400#M.
In order of increasing inhibitory activity, the most potent compounds found were SQ 22536, 2',5'-dideoxyadenosine and 2'-deoxyadenosine 3'-phosphate (Table 1) . It is of interest that modification of 2'-deoxyadenosine, either by removal of the 5'-oxygen atom or by addition of a 3'-phosphate residue, greatly enhanced its inhibitory activity.
Compound SQ 22536 and 2',5'-dideoxyadenosine were the only inhibitors of platelet adenylate cyclase listed in Table 1 that were found to have marked effects in intact platelets, so further studies on particulate-fraction adenylate cyclase were carried out with these two compounds. Previous observations had indicated that, when platelet adenylate cyclase was activated by PGEj, adenosine lacked stimulatory activity and appeared to be a more effective inhibitor of the enzyme than in the absence of PGE1 (Haslam & Lynham, 1972) . The effects of 2',5'-dideoxyadenosine and of compound SQ 22536 were therefore compared in the presence and absence of 1 pM-PGE,. The percentage changes in adenylate cyclase activities in three such experiments, which were much less variable than the specific activities of the different enzyme preparations, are shown in Table 2 as mean values ±S.E.M. With 20400,uM-2',5'-dideoxyadenosine, more potent inhibitions of platelet adenylate cyclase were observed in the presence than in the absence of PGE, (77-94% and 66-85% respectively), though the differences were much smaller than those seen with 400/tM-adenosine.
However, with 20-4004uM-compound SQ 22536 there was no significant effect of PGE1 on the inhibitions observed (57-84 %). As a result, the difference between the inhibitory activities of 2',5'-dideoxyadenosine and compound SQ 22536 was only statistically significant at lower concentrations (<20.UM) in the absence of PGE1, but was significant at all concentrations up to 400,UM in the presence of PGE1 (2P < 0.05, Student's t test). At the highest concentration tested (2mM; not shown in Table 2 ), 2',5'-dideoxyadenosine and compound SQ 22536 inhibited PGEI-activated adenylate cyclase activity by 96 and 90% respectively.
The kinetics of the inhibition of platelet adenylate cyclase by 2',5'-dideoxyadenosine and compound SQ 22536 were studied in the presence of PGE1. Adenylate cyclase activity was linear for at least 10min at all MgATP concentrations from 0.04mM to 1.Omm, both in the presence and absence of these inhibitors. Results from three experiments, one of which is shown in Fig. 1 , indicated that the inhibitions were non-competitive and that the Km value for MgATP was about 60AM. As the doublereciprocal plots intersected on or close to the abscissa the non-competitive inhibition approximates to the simple type. Studies with a range of inhibitor concentrations indicated that the IC50 values were 4,UM for 2',5'-dideoxyadenosine and 13pM for compound SQ 22536 and showed that the 1978 Table 2 . Effects of adenosine, 2',5'-dideoxyadenosine and compound SQ 22536 on the basal and PGE1-stimulated adenylate cyclase activities ofplatelet particulate fraction In each of three experiments, the changes in adenylate cyclase activities observed in the presence of adenosine or analogues were calculated as percentages of the corresponding control activity in the presence or absence of 1 uM-PGE1. Mean values ±S.E.M. for the percentage changes in activity in the three experiments are given. The significance of changes (Student's t test) are indicated as follows: *2P < 0.05; **2P < 0.01. PGE1 increased adenylate cyclase activity from 0.43 ± 0.13 nmol of cyclic AMP formed/lOmin per mg of protein to 7.2 ± 2.2nmol of cyclic AMP formed/lOmin per mg of protein in these three experiments (mean values ± S.E.M.). (Fig. 3) .
With PGE, alone, 2',5'-dideoxyadenosine was substantially more effective than compound SQ 22536, particularly at concentrations below 50M (Fig. 3a) . More than 80% inhibition of the increase in cyclic [3H]AMP in response to PGE1 alone was observed with concentrations of 2',5'-dideoxyadenosine over 100puM. However, in the presence of 2mM-papaverine, the inhibitory effects of both 2',5'-dideoxyadenosine and compound SQ 22536 were less powerful (Figs. 3b and 3c) . Moreover, the former compound appeared to be only slightly more effective than the latter in the presence of both PGE, and papaverine, and there was little difference between their activities in the presence of papaverine alone.
Approx. 200,UM-2',5'-dideoxyadenosine or compound SQ 22536 was required to inhibit the accumulation of cyclic [3H]AMP caused by 2mM-papaverine with or without PGE1 by 50%.
Because of an apparent similarity between the actions of the inhibitory nucleosides and of ADP on adenylate cyclase in intact platelets, we studied the effect on the action of 2',5'-dideoxyadenosine of Nethylmaleimide, which blocks the inhibition of adenylate cyclase by ADP (Mills, 1974) . Table 3 shows that 0.4mM-N-ethylmaleimide caused a moderate increase in the accumulation of cyclic
[3H]AMP in platelets in response to PGE, alone and completely prevented the inhibition of the effect of PGE, by ADP. However, 0.4mM-N-ethylmaleimide had no effect on the inhibition of cyclic [3H]AMP accumulation by 2',5'-dideoxyadenosine (Table 3) .
Effects of 2',5'-dideoxyadenosine and of compound SQ 22536 on the inhibition ofplatelet aggregation by PGE1
The inhibition of ADP-induced platelet aggregation by prior addition of PGE1 was markedly diminished by 100,lM-2',5'-dideoxyadenosine added with the PGEI, as also was the increase in platelet cyclic [3H] AMP that preceded the addition of ADP (Fig. 4) . Compound SQ 22536 at 100#M was slightly Vol. 176 less potent than 2',5'-dideoxyadenosine in both respects. Essentially the same effects of these adenosine analogues on both the inhibition of platelet aggregation by PGE, and the associated increase in platelet cyclic [3H]AMP were observed in two further experiments with ADP as the aggregating agent and in three experiments with [arginine]-vasopressin as the aggregating agent (e.g. Fig. 5 ). However, as reported previously (Haslam & Rosson, 1972; Haslam, 1975) (Haslam, 1975) . In each experiment, the inhibition of aggregation was related to the concentration of platelet cyclic [3H]AMP resulting from the combined actions of PGEI, adenosine analogue and aggregating agent (Figs. 4 and 5) . However, the extent to which 100uM-2',5'-dideoxyadenosine proved more effective than 100,uM-compound SQ 22536 in reversing the inhibition of platelet aggregation by PGE1 varied widely from experiment to experiment (e.g. Figs. 4-6 ). This may be explained by the observation that a relatively small decrease in the elevation of platelet cyclic [3H]AMP concentration by PGE1 was often associated with a transition from Figs. 5c and 5d ). Thus the difference between the effects of 2',5'-dideoxyadenosine and compound SQ 22536 was much smaller when the PGE1 concentration was sufficiently low for both compounds to transform a primary aggregation response into an irreversible aggregation (Fig. 6a ) than when, with twice the PGE, concentration, only 2',5'-dideoxyadenosine was able to do so (Fig. 6b) with ADP) in the absence of the adenosine analogues, so as to maximize the chances of detecting potentiation in the presence of these compounds. However, the only significant changes were slight inhibitions of the release of 5-hydroxy[14C]tryptamine induced by collagen that were occasionally observed with 2',5'-dideoxyadenosine (Table 4) . Table 4 . Effects of 2',5'-dideoxyadenosine and of compound SQ 22536 on the platelet aggregation and release of 5-hydroxy-
[14C]tryptamine from platelets induced by collagen Incubation mixtures consisting of 0.85ml of platelet-rich plasma labelled with 5-hydroxy-['4C]tryptamine and a final total of 0.15ml of additions in 0.154M-NaCl were stirred in an aggregometer. 2',5'-Dideoxyadenosine or compound SQ 22536 (final concentrations 100pUM) or an equivalent volume of 0.154M-NaCI was added 30s before collagen (final concentrations indicated). Aggregation was recorded for 2min before addition of 0.2ml of 9%4 (w/v) paraformaldehyde and measurement of the release of platelet 5-hydroxy[V4C]tryptamine. For each concentration of collagen tested three aggregation and release measurements were made both with and without added compound. The sequence of these tests was randomized. The significance of any differences observed was evaluated by unpaired Student's t tests (NS indicates 2P > 0.05). s.c., An increase in absorbance occurred, indicating a platelet shape change without aggregation.
Expt.
Anti In general, 2-substituted and N6-monosubstituted adenosines were found to be activators of platelet particulate-fraction adenylate cyclase, whereas deoxyadenosines had no stimulatory activity. The most potent stimulatory adenosine analogue that also lacked inhibitory activity against adenylate cyclase at high concentrations was 2-azidoadenosine. Those analogues previously found to be inhibitors of human platelet aggregation (Born et al., 1965; Kikugawa et al., 1973a,b; Agarwal & Parks, 1975; Cusack & Born, 1977) were also found to activate platelet adenylate cyclase, providing further evidence that the effects of these compounds on platelet aggregation are mediated by increases in platelet cyclic AMP. Similar structure-activity relationships have been found for the ability of adenosine analogues to increase cyclic AMP concentrations in brain tissue (Huang et al., 1972) and myocardium (Huang & Drummond, 1976) .
The inhibitory activity of adenosine on platelet adenylate cyclase was, in contrast with its stimulatory activity, markedly decreased or abolished by 2-substituents or N6-monosubstitution and was enhanced by removal of oxygen atoms from the ribosyl moiety. These results are consistent with those obtained in a study of the inhibitory effects of adenosine analogues on hepatic adenylate cyclase (Londos & Preston, 1977) . The most potent inhibitor of platelet adenylate cyclase that we found was 2'-deoxyadenosine 3'-monophosphate, reported by Sahyoun et al. (1976a) to be a naturally occurring inhibitor of adenylate cyclase; 2',5'-dideoxyadenosine was slightly less active and compound SQ 22536 was less active again. Relative to these three compounds, the 2'-deoxy-, 3'-deoxy-and 5'-deoxyadenosines were much weaker inhibitors. Adenosine analogues could, in principle, act as antagonists of the stimulatory action of adenosine, as well as being inhibitors in their own right, and 2'-deoxyadenosine (Shimizu et al., 1975) and 5'-deoxyadenosine (Huang & Drummond, 1976) have been reported to show such antagonist activities in brain and heart preparations respectively. However, as less than one-third of the basal adenylate cyclase activity of platelet particulate fraction can be attributed to the stimulatory effect of traces of adenosine in the assay (unpublished observations on the effects of adenosine deaminase; R. J. Haslam The structure-activity relationships for activation and inhibition of adenylate cyclase by adenosine analogues reported here and in studies with other tissues indicate that the optimal molecular configurations required for the two effects are quite different, and strongly support our previous evidence that adenosine exerts independent stimulatory and inhibitory effects on the enzyme at different binding sites (Haslam & Lynham, 1972; Haslam & Rosson, 1975) .* Conformational studies on adenosine and its analogues provide further support for this conclusion (Miles et al., 1977) .
Mechanism of inhibition ofplatelet adenylate cyclase by adenosine and its analogues A previous study with intact platelets in which the uptake of adenosine was blocked with p-nitrobenzylthioguanosine indicated that the stimulatory action of adenosine on adenylate cyclase was mediated by externally oriented membrane receptors, and that the inhibitory action of the compound which was much diminished in intact platelets was exerted intracellularly, presumably at a site on or close to the catalytic subunit of the enzyme (Haslam & Rosson, 1975) . The latter conclusion is supported by the present finding that 2',5'-dideoxyadenosine and compound SQ 22536 inhibited adenylate cyclase in intact platelets, whereas 2'-deoxyadenosine 3'-monophosphate, an even more potent inhibitor of the particulate-fraction adenylate cyclase, did not appear to do so. Presumably, 2'-deoxyadenosine 3'-monophosphate, like other nucleotides, is unable to penetrate the platelet plasma membrane.
Our observations that 2',5'-dideoxyadenosine and compound SQ 22536 inhibited platelet adenylate cyclase non-competitively with respect to MgATP and that the former and possibly the latter compound showed negative co-operativity are consistent with similar reports for the inhibition of lung adenylate cyclase by compound SQ 22536 (Weinryb & Michel, 1974) and of adipocyte adenylate cyclase by 2'-deoxyadenosine 3'-monophosphate (Sahyoun et al., 1976b) . 2',5'-Dideoxyadenosine has also been shown to inhibit fat-cell (Fain et al., 1972 ), epithelial-cell (Zenser, 1976 and liver (Londos & Preston, 1977) adenylate cyclases, but we are not aware of any kinetic study with this compound. The inhibitory action of adenosine has been reported to have * Shortly after submission of this paper for publication, a report (Londos & Wolff, 1977) appeared which described the effects of adenosine analogues on adenylate cyclases from several tissues, including platelets, from which essentially the same conclusion was drawn.
Vol. 176 similar kinetic properties to those we observed for the more potent deoxy analogues (McKenzie & Bar, 1973; Londos & Preston, 1977) . With liver membranes, adenosine has also been shown to act at sites distinct from those through which glucagon, Mg2+ ions and GTP promote adenylate cyclase activity (Londos & Preston, 1977) .
As noted before (Haslam & Lynham, 1972) , adenosine appeared to be a much more potent inhibitor of platelet adenylate cyclase in the presence than in the absence of PGEj. This difference was much less marked with 2',5'-dideoxyadenosine and was absent with compound SQ 22536. Measurement of the inhibitory action of adenosine in the absence of PGE, is complicated by the simultaneous and independent stimulation of the enzyme by the compound, so it is difficult to determine with the platelet enzyme whether PGE1 has a real effect on the inhibitory component of the action of adenosine. This, however, may be the case, as adenosine has been shown to inhibit adenylate cyclase more powerfully in the presence of stimulatory hormones in other tissues in which the enzyme was not activated by adenosine (McKenzie & Bar, 1973; Londos & Preston, 1977) .
Inhibition of platelet adenylate cyclase by adenosine analogues in intact platelets
Both 2',5'-dideoxyadenosine and compound SQ 22536 were effective inhibitors of the basal and PGE,-stimulated adenylate cyclase activities of intact platelets, when these were measured as the increases in labelled cyclic AMP in platelets that had been preincubated with labelled adenine and then incubated briefly with papaverine or papaverine and PGEj. Papaverine was added to block cyclic AMP phosphodiesterase, but, as the adenosine analogues studied suppressed the increases in labelled cyclic AMP caused by PGE1 more effectively in the absence than in the presence of papaverine, it is possible that papaverine also decreased their rate of entry into the platelets. Moreover, the greater effectiveness of 2',5'-dideoxyadenosine relative to compound SQ 22536 in the absence of papaverine might reflect a differential effect of papaverine on the entry of the two compounds. Papaverine is known to inhibit one of the mechanisms responsible for the transport of adenosine into platelets (Haslam & Rosson, 1975; Sixma et al., 1976) . The alternative explanation of these observations, that these adenosine analogues potentiate cyclic AMP phosphodiesterase as well as inhibiting adenylate cyclase, seems less probable, but has not been eliminated. The inhibition of platelet adenylate cyclase by deoxyadenosine compounds differed in two respects from the inhibitory action on the enzyme of the aggregating agent ADP; thus the effect of the latter is observed in intact but not broken platelets (Salzman & Levine, 1971; Haslam, 1973) and is blocked by N-ethylmaleimide (Mills, 1974) .
Our observations, that 2',5'-dideoxyadenosine and compound SQ 22536 markedly decrease both the inhibition of platelet aggregation and the associated increase in platelet cyclic AMP caused by PGEj, confirm and extend the preliminary report by Harris et al. (1975) on the effects of compound SQ 22536. These results are in accord with a large body of evidence indicating that the effect of PGE, on platelet aggregation is mediated by cyclic AMP formed as a result of the activation of adenylate cyclase (for reviews see Haslam, 1975 see Haslam, , 1978 Haslam et al., 1978) . Moreover, our experiments suggest that the criteria of Sutherland et al. (1968) for identification of cyclic AMP as the second messenger of hormone or drug action in other biological systems could be increased to include the results of studies with 2',5'-dideoxyadenosine or related compounds as potential inhibitors of adenylate cyclase. In the only previous attempts to use 2',5'-dideoxyadenosine in this manner known to us, it was found that, in contrast with adenosine itself, which appears to act by a different mechanism, 2',5'-dideoxyadenosine blocked the hormone-stimulated accumulation of cyclic AMP in fat-cells and liver cells, but did not inhibit lipolysis or glycogenolysis (Fain et al., 1972; Fain & Shepherd, 1977) . These observations were interpreted as indicating that factors in addition to cyclic AMP are involved in the regulation of these processes (Fain & Shepherd, 1977; Moreno & Fain, 1978) . Another material known to inhibit adenylate cyclase from many tissues is the adenylate cyclase inhibitor obtained from rat liver perfusate (Levey et al., 1975) , which, however, also affects guanylate cyclase and cyclic GMP phosphodiesterase (Lehotay et al., 1977) . The specificity of 2',5'-dideoxyadenosine and related compounds remains to be established.
Lack of effect of inhibition of adenylate cyclase on platelet function in the absence of drugs that increase platelet cyclic AMP As both 2',5'-dideoxyadenosine and compound SQ 22536 inhibited the basal adenylate cyclase activity in intact platelets, these compounds should, in principle, decrease the steady-state concentration of cyclic AMP in resting platelets. Although no decrease in the cyclic [3H]AMP extracted from labelled platelets was detected, it may be very difficult to measure decreases in platelet cyclic AMP because of some form of compartmentation of the compound (Haslam, 1975) . Whether a decrease in platelet cyclic AMP will affect platelet function will presumably depend on whether or not the steadystate concentration in resting platelets is sufficient to activate to some extent the cyclic AMP-dependent protein kinases involved in the effects of increased cyclic AMP concentrations. This cannot be predicted without investigation and it is, therefore, of great interest that neither 2',5'-dideoxyadenosine nor compound SQ 22536 caused aggregation or potentiated aggregation or release of 5-hydroxy['4C]-tryptamine induced by any of the aggregating agents studied. These results are consistent with previous evidence (Haslam, 1975 (Haslam, , 1978 ) that a decrease in platelet cyclic AMP is not required for aggregation to occur, and show more convincingly than has previously been possible that the basal concentration of cyclic AMP in platelets is too low to have any significant functional role. Thus our results indicate that cyclic AMP is an essentially unidirectional regulator of platelet function.
These results and conclusions are in conflict with a preliminary report from another laboratory , in which compound SQ 22536 was found to potentiate the effects of critical concentrations of certain aggregating agents, including ADP, collagen and arachidonate, but not vasopressin. However, despite reinvestigation with freshly synthesized compound SQ 22536, we were not able to detect any potentiating effects in the absence of PGEj. In addition, the observation by Salzman et al. (1977) that compound SQ 22536 could potentiate the action of ADP, which itself inhibits adenylate cyclase, but not that of vasopressin, which does not, is in apparent conflict with the relative effects of compound SQ 22536 on the inhibitions of ADP-and vasopressin-induced aggregation by PGE1. Salzman (1977) has also reported that compound SQ 22536 potentiates aggregation induced by prostaglandin G2. This could be due to inhibition by compound SQ 22536 of cyclic AMP formation induced by prostaglandin D2, which is generated from prostaglandin G2 in platelet-rich plasma (Smith et al., 1976) and is a known activator of platelet adenylate cyclase (Mills & Macfarlane, 1974 
